P007 Galectin-1 inhibits hematopoietic stem and progenitor cell mobilization

✍ Scribed by J. Kiss; A. Kunstár; R. Fajka-Boja; V. Dudics; J. Tóvári; Á. Légrádi; Ė. Monostori; F. Uher

• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 49 KB
• Volume: 21
• Category: Article
• ISSN: 0268-960X
• DOI: 10.1016/s0268-960x(07)70080-2

✦ Synopsis

26.1%) patients after PR, in 9 (39.1%) after HCT and in 7 (30.4%) at the time of BM recovery. GPBB became elevated in 5 (21.7%) patients after PR, in 5 (21.7%) after HCT and remained elevated in 2 (8.7%) at the time BM recovery. CK-MB mass, cTnT, cTnI, FABP remained negative after PR and HCT in all patients. Conclusion: Our results suggest that administration of PR and HCT is in most acute leukemia patients associated with acute neurohumoral activation (significant rise in NT-proBNP). In our study, NT-proBNP remained markedly elevated in 7 (30.4%) patients at the time of BM recovery. These persistent NT-proBNP elevations indicate subclinical cardiotoxicity (risk for development of heart failure) and require further follow-up. From markers of myocardial ischemia and necrosis, only GPBB became elevated after PR and HCT. These changes could be considered a sign of subclinical cardiotoxicity. CK-MB mass, cTnT, cTnI, FABP does not seem to be of value in detection of cardiotoxicity in peritransplant period. These findings need to be confirmed in larger studies with longer follow-up.